Xtant Medical Completes $21.4 Million Deals with Companion Spine for Orthopedic Assets

Xtant Medical Completes Major Transactions with Companion Spine

Xtant Medical Holdings, Inc. has recently completed significant transactions with Companion Spine, solidifying its position in the orthopedic sector. On March 2, 2026, the company announced the receipt of $10.7 million, part of a larger sum associated with Companion Spine's acquisition of Xtant’s Coflex® assets and the Paradigm OUS businesses. This finalized agreement pushes the total amount for these transactions to a remarkable $21.4 million.

The breakdown of the latest payment includes $8.2 million, which settles an unsecured promissory note previously issued by Companion Spine, alongside accrued interest. An additional $2.2 million pertains to the resolution of working capital and other necessary purchase price adjustments.

Sean Browne, the President and CEO of Xtant Medical, expressed satisfaction with the finalization of these transactions, stating that it facilitates a clearer focus on their high-margin biologics business. He acknowledged that the partnership with Companion Spine places these assets into the hands of a recognized leader in the neuro-musculoskeletal domain, which could help unlock the full potential of these motion preservation technologies. Browne also highlighted the significance of the funding received, indicating that it would enable them to further lower long-term debt and improve cash liquidity, strategically benefiting the company’s future.

About Xtant Medical Holdings, Inc.

Xtant Medical has a mission deeply rooted in honoring the act of donation, allowing patients to lead fulfilling and complete lives. As a global medical technology company, it centers its focus on the design, development, and commercialization of a comprehensive portfolio of orthobiologics aimed at chronic and surgical wound care, sports medicine markets, and spinal implant systems. With a commitment to integrity and customer service, Xtant Medical employs dedicated personnel who strive for excellence.

This strategic move not only mitigates the financial obligations of Xtant Medical but also places it in a more resilient position within the medical technology landscape. The company's ongoing efforts and enhanced liquidity are expected to drive growth and innovation in their remaining business spheres, particularly in the biologics market.

While the trajectory of Xtant Medical appears promising, Browne cautioned investors about the inherent risks tied to forward-looking statements, emphasizing that actual outcomes could diverge due to various factors, including operational performance and market influences.

Investors are recommended to refer to Xtant Medical’s filings with the Securities and Exchange Commission (SEC) for comprehensive insights into their financial conditions and related risks. These documents are available for public viewing, making it easier for stakeholders to stay informed about the company’s strategic decisions and financial forecasts.

In summary, the completion of these transactions marks a pivotal moment for Xtant Medical, reinforcing its future aspirations and operational focus amid a competitive landscape. The partnership with Companion Spine symbolizes an alignment that could potentially yield beneficial outcomes for both entities involved.